FindTrial
Sign In

Identification of the Origin Cell of Pancreatic Neuroendocrine Neoplasms Based on the "Chromosome Amplification" Feature

Identification of the Origin Cell of Pancreatic Neuroendocrine Neoplasms Based on the "Chromosome Amplification" Feature

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600127135
Enrollment
Unknown
Registered
2026-06-25
Start date
2026-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Neuroendocrine Tumors

Interventions

Chromosomally amplified PanNETs.:None
Chromosomally neutral PanNETs.:None

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. 18~80 years old; 2. Patients with clinically suspected PanNETs, including non-functional PanNETs, insulinomas, glucagonomas, gastrinomas, and others. 3. Scheduled for surgical intervention. 4. Informed consent obtained from the patient.

Exclusion criteria

Exclusion criteria: 1. The tumor was too small to be sampled for relevant testing; 2. Postoperative pathology excluded the pancreatic neuroendocrine tumo.

Design outcomes

Primary

MeasureTime frame
Chromosomal copy number variation.;Transcriptomic profiles of tumor cells;—

Countries

China

Contacts

Public ContactXiafei Hong

Peking Union Medical College Hospital

hongxiafei@pumch.cn+86 10 6915 2601

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 3, 2026